Most Awaited Q3 Sale is back. Upto 30% discount on every report.

Thalassemia Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 June 07
SKU : PH2148
180 pages
Report Summary
Table of Contents
List of Tables & Figures

Thalassemia Treatment Market is segmented By Disease Type (Alpha Thalassemia, Beta Thalassemia), By Treatment Type (Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Gene Therapy, Surgery), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030 


Thalassemia Treatment Market Report Overview

The Thalassemia Treatment Market report analyzes the global market size, shares, recent trends, competitive intelligence, and future market outlook. Thalassemia is a genetic blood disorder that affects the production of hemoglobin. The market is driven by advancements in gene therapy and stem cell transplantation, increasing awareness and screening programs, and the availability of favorable reimbursement policies. In Europe, the Thalassemia Treatment Market is experiencing substantial growth. Key players in the market include Bluebird Bio, Inc., Novartis AG, Acceleron Pharma, Inc., and other prominent players.

Thalassemia is an inherited blood disorder that reduces the production of functional hemoglobin, the protein in red blood cells that carries oxygen. This causes a shortage of red blood cells and low oxygen levels in the bloodstream, leading to various health problems. Signs and symptoms vary but may include mild to severe anemia, paleness, fatigue, yellow discoloration of the skin, and bone problems. When there are not enough healthy red blood cells, there is also not enough oxygen delivered to all the other cells of the body, which may cause a person to feel tired, weak, or short of breath. This is a condition called anemia. People with thalassemia may have mild or severe anemia. Severe anemia can damage organs and lead to death.

As per DataM Intelligence, the Thalassemia Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Thalassemia Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Thalassemia Treatment Market in the United States and Canada produces the utmost share. Whereas the European Thalassemia Treatment Market is projected to continue its presence globally from 2023 to 2030.


Thalassemia Treatment Market Summary and Scope



Market CAGR


Segments Covered

By Disease Type, By Treatment Type, By Route of Administration, By End User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America


For more insights - Download the Sample


Thalassemia Treatment Market Trends and Dynamics

The thalassemia treatment market growth is driven by several factors, such as an increase in the prevalence of thalassemia, a rise in global awareness, and, increasing investment in research and development. 

The rising awareness about thalassemia is expected to drive market growth. 

An increase in awareness about thalassemia is very important for the prevention of the disease. Many organizations are working towards this cause by initiating awareness campaigns. Governments of countries are also supporting the cause by investing in these programs. For instance, International Thalassaemia Day is celebrated on May 8 to raise awareness amongst people concerned with decision and policymaking, health care professionals, patients and their families, and the community at large about thalassemia. The majority of the population is unaware of the disease, especially in more prevalent areas, such as the Asia Pacific and the Mediterranean. The Center for Disease Control and Prevention (CDC) funds one project that monitors blood safety in people with blood disorders. This project is called “Characterizing the Complications Associated with Therapeutic Blood Transfusions for Hemoglobinopathies.” Georgia State University, the University of Florida, and the University of California at San Francisco Benioff Children’s Hospital Oakland have been awarded funding to look at transfusion-related complications in people with hemoglobin disorders (sickle cell disease and thalassemia) and develop approaches for reducing these complications. Besides, CDC funds the Association of Public Health Laboratories to provide public health technical assistance with screening (a test to look for a disease before it is noticeable) activities, including needs assessments for laboratories, as well as education for patients, caregivers, and healthcare workers on hemoglobinopathy screening programs. 

The high cost of treatment is expected to hinder global thalassemia treatment market growth.

The high cost of treatment is expected to hamper the global thalassemia treatment market growth. 

Industry analysis.

The global thalassemia treatment market report will provide an in-depth analysis of the market based on various industry factors such as Porter`s five forces, innovations, new product launches, pricing analysis, and pipeline analysis.

COVID-19 Impact on Thalassemia Treatment Market Growth

COVID-19 has significantly impacted the global Thalassemia Treatment market. Since COVID-19 containment protocols, the supply chain of many market players was disrupted and caused a lack of raw materials to disturb the supply and demand chain. Furthermore, because of the socializing restrictions, regular healthcare checkups were difficult, leaving most patients with thalassemia undetected, negatively impacting the global Thalassemia Treatment market growth during the pandemic.

Thalassemia Treatment Market Segment

The alpha-thalassemia is expected to dominate the thalassemia treatment market throughout the forecast period (2023-2030)

Alpha thalassemia is expected to hold the largest market share over the period forecast (2022-2029) owning to a higher prevalence of the disease globally. According to National Organization for Rare Disorders, alpha thalassemia occurs in 4-20 individuals per every 1,000 births. Alpha thalassemia is found in most populations worldwide but is most common in the Middle East, Southeast Asia, and certain Mediterranean countries. Doctors in Europe and North America are also increasingly encountering patients with alpha-thalassemia due to increased migration. Alpha-thalassemia is an inherited disease caused by mutations in a gene required for making a component of hemoglobin. Those mutations either prevent or reduce the production of hemoglobin, which can cause a shortage of mature red blood cells and lead to anemia. The mutations that cause alpha-thalassemia are more common in Asia, India, the Middle East, and the Mediterranean where they are found in up to 20% of the population. But the increase in modern migration means that cases are now cropping up more often in other regions. Southern Mediterranean countries recognize the rise in patients with alpha-thalassemia and have increased resources to meet the growing demand appropriately, hence increasing the market for alpha-thalassemia treatment globally. 

Thalassemia Treatment Market Geographical Share

The North American region holds the largest market share of the global thalassemia treatment market. 

North America is dominating the thalassemia treatment market in 2018 and is estimated to hold the largest market size over the forecast period (2023-2030), owing to an increase in thalassemia incidences, a highly aware population, advanced healthcare infrastructure, and favorable government initiatives. The cases of thalassemia disorder are increasing in the region due to migration. Thalassemia, once a rarity in the US, is increasingly encountered in clinical practice due to shifts in immigration. Thalassemia is becoming more prevalent in the US due to the immigration of people from affected regions; according to Cooley's Anemia Foundation, 12% of patients with β‐thalassemia in their US patient database were adopted from other countries. Furthermore, many organizations and societies are working in this region to spread awareness about thalassemia and ensure its dominance over the global market. 

Thalassemia Treatment Market Industries and Competitive Landscape

Some of the major key players in the market are Vifor Pharma, Kiadis Pharma, Gamida Cell, ApoPharma, bluebird bio, Inc., Novartis AG, Bristol-Myers Squibb Company, Celgene Corporation, La Jolla Pharmaceutical, Sangamo Biosciences, and Acceleron Pharma. In the thalassemia treatment market, bluebird bio-Inc. will dominate the market, owning to portfolio expansion, mergers, collaborations, and acquisitions. The key players are adopting various growth strategies such as mergers & acquisitions, partnerships, and collaborations and increasing research and development and high investment, which are contributing to the growth of the thalassemia treatment market globally. For instance, on April 16, 2021, Sanofi acquired Kiadis. Also, on December 22, 2021, Novartis acquired Gyroscope Therapeutics. 

Bristol-Myers Squibb Company 


The Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York City. BMS is a leading pharmaceutical company and has consistently ranked among the largest U.S. corporations. For fiscal 2021, it had total revenue of $46.4 billion. 

Product Portfolio:

 The product portfolio of Bristol-Myers Squibb Company for thalassemia treatment contains REBLOZYL.

The global thalassemia treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and a range of 200 (approximate) pages

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy
Request new version
What is the Projected CAGR value of the Thalassemia Treatment Market?
Thalassemia Treatment Market is expected to grow at a CAGR of 10.5% during the forecasting period 2023-2030.
Which region controlled the global market during 2023-2030?
North American region Controls the Thalassemia Treatment Market during 2023-2030.
Which is the fastest-growing region in the Thalassemia Treatment Market?
Among all regions, Asia Pacific is the fastest-growing market share during the forecast period.
Which Companies Are Included in the Thalassemia Treatment Market?
Vifor Pharma, Kiadis Pharma, Gamida Cell, ApoPharma, bluebird bio, Inc., Novartis AG, Bristol-Myers Squibb Company, Celgene Corporation, La Jolla Pharmaceutical, Sangamo Biosciences, and Acceleron Pharma.
Related Reports

Acinetobacter Infections Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 September 21
Starting from



Allergen Blocker Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2022 July 07
Starting from



Eczema Therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 May 12
Starting from



Achalasia Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 September 21
Starting from



Melasma Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2022 December 29
Starting from



Xerophthalmia Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 January 06
Starting from